Xenogen Corporation, a leading-edge biotechnology company, provides R&D discovery solutions to the pharmaceutical, biotechnology, and chemical manufacturing industries through offering imaging and transgenic technologies. Xenogen Corporation is the exclusive patent licensee of in vivo biophotonic imaging technology, which measures light emitted from sources within a living mammal. New products and services from Xenogen that utilize this proprietary technology help researchers to visualize biological processes in living mammals, as they happen. This novel approach spans virtually all areas of therapeutic investigation and can expedite the drug discovery and development process, thereby offering pharmaceutical and chemical manufacturers the potential to save both time and money in taking products to market.


Date Type Amount Investors Valuation
08/15/05 Series D 18M Abingworth Management, Brentwood Venture Capital, CMEA Ventures, Delphi Ventures, Harvard Private Capital Holdings, Lombard Odier, Partners for Growth, SR One Limited, SVB Capital, Versant Ventures, Chevron Techologies Unknown


Michael Sterns (Chief Business Officer)

Alan Goldberg (Board Member)

Bradley Rice (CTO)

Robert Breckon (Board Member)

Michael Bigham (Board Member)

View more details about all 17 people at Xenogen